JP2023545501A - 血液障害を処置するための組成物及び方法 - Google Patents

血液障害を処置するための組成物及び方法 Download PDF

Info

Publication number
JP2023545501A
JP2023545501A JP2023522978A JP2023522978A JP2023545501A JP 2023545501 A JP2023545501 A JP 2023545501A JP 2023522978 A JP2023522978 A JP 2023522978A JP 2023522978 A JP2023522978 A JP 2023522978A JP 2023545501 A JP2023545501 A JP 2023545501A
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
thrombocytopenia
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023522978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545501A5 (https=
JPWO2022081997A5 (https=
Inventor
イェドノック，テッド
サンカラナラヤナン，セテュ
Original Assignee
アネクソン，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アネクソン，インコーポレーテッド filed Critical アネクソン，インコーポレーテッド
Publication of JP2023545501A publication Critical patent/JP2023545501A/ja
Publication of JP2023545501A5 publication Critical patent/JP2023545501A5/ja
Publication of JPWO2022081997A5 publication Critical patent/JPWO2022081997A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023522978A 2020-10-16 2021-10-15 血液障害を処置するための組成物及び方法 Pending JP2023545501A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063093029P 2020-10-16 2020-10-16
US63/093,029 2020-10-16
PCT/US2021/055216 WO2022081997A1 (en) 2020-10-16 2021-10-15 Compositions and methods for treating blood disorders

Publications (3)

Publication Number Publication Date
JP2023545501A true JP2023545501A (ja) 2023-10-30
JP2023545501A5 JP2023545501A5 (https=) 2024-10-22
JPWO2022081997A5 JPWO2022081997A5 (https=) 2024-10-22

Family

ID=81208704

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023522978A Pending JP2023545501A (ja) 2020-10-16 2021-10-15 血液障害を処置するための組成物及び方法

Country Status (8)

Country Link
US (1) US20230391858A1 (https=)
EP (1) EP4228696A4 (https=)
JP (1) JP2023545501A (https=)
KR (1) KR20230087572A (https=)
AU (1) AU2021361067A1 (https=)
CA (1) CA3195798A1 (https=)
MX (1) MX2023004429A (https=)
WO (1) WO2022081997A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006507A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
WO2023114763A1 (en) * 2021-12-13 2023-06-22 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016526393A (ja) * 2013-07-09 2016-09-05 アネクソン，インコーポレーテッド 抗補体因子Ｃ１ｑ抗体及びその使用
JP2018501813A (ja) * 2014-11-05 2018-01-25 アネクソン，インコーポレーテッド ヒト化抗補体因子Ｃ１ｑ抗体及びその使用
JP2019501132A (ja) * 2015-11-24 2019-01-17 アネクソン，インコーポレーテッド 抗補体因子Ｃ１ｑ Ｆａｂ断片及びその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021076991A1 (en) * 2019-10-17 2021-04-22 Annexon, Inc. Compositions and methods for treating blood disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016526393A (ja) * 2013-07-09 2016-09-05 アネクソン，インコーポレーテッド 抗補体因子Ｃ１ｑ抗体及びその使用
JP2018501813A (ja) * 2014-11-05 2018-01-25 アネクソン，インコーポレーテッド ヒト化抗補体因子Ｃ１ｑ抗体及びその使用
JP2019501132A (ja) * 2015-11-24 2019-01-17 アネクソン，インコーポレーテッド 抗補体因子Ｃ１ｑ Ｆａｂ断片及びその使用

Also Published As

Publication number Publication date
AU2021361067A1 (en) 2023-06-01
EP4228696A1 (en) 2023-08-23
US20230391858A1 (en) 2023-12-07
WO2022081997A1 (en) 2022-04-21
EP4228696A4 (en) 2025-03-26
AU2021361067A9 (en) 2024-07-11
CA3195798A1 (en) 2022-04-21
KR20230087572A (ko) 2023-06-16
MX2023004429A (es) 2023-07-11

Similar Documents

Publication Publication Date Title
JP7809056B2 (ja) 血液障害を処置するための組成物及び方法
JP6339574B2 (ja) 抗ｍｃａｍ抗体及び関連する使用方法
JP7499760B2 (ja) 脳損傷を治療するための組成物及び方法
US20170152309A1 (en) Anti-complement factor c1q fab fragments and uses thereof
KR20190005944A (ko) 척수성 근위축 치료용 조성물 및 방법
WO2018017711A1 (en) Compositions and methods for treating frontotemporal dementia
JP2023545501A (ja) 血液障害を処置するための組成物及び方法
CN115996752A (zh) 用于治疗癫痫的组合物和方法
HK40077291A (en) Compositions and methods for treating blood disorders
RU2786053C2 (ru) Фармацевтическая композиция для применения для лечения или предупреждения с5-связанного заболевания и способ лечения или предупреждения с5-связанного заболевания
RU2789389C2 (ru) Фармацевтическая композиция, предназначенная для применения для лечения или предупреждения связанного с с5 заболевания, и способ лечения или предупреждения связанного с с5 заболевания
RU2832946C2 (ru) Фармацевтическая композиция, предназначенная для применения для лечения или предупреждения связанного с c5 заболевания, и способ лечения или предупреждения связанного с c5 заболевания

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230517

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260302